NPASS Compound

Structure

CID329277 OpenBabel06191716202D 49 52 0 0 1 0 0 0 0 0999 V2000 -5.7105 1.7862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.1959 7.5523 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -4.7160 1.6817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.7837 6.7433 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.8660 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 4.8660 3.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.7321 1.0000 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 4.8660 4.5000 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 -6.2983 0.9772 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 2.6027 8.4659 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.8366 0.0055 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 5.6750 5.0878 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 -2.8147 -0.2024 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 5.3660 6.0388 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 -3.3147 0.6636 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 4.3660 6.0388 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 -4.8970 -0.0409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 4.1850 7.7614 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -5.8916 0.0636 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 3.5972 8.5704 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -4.3092 0.7681 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 3.7782 6.8479 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 -7.2928 1.0817 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.0149 9.2749 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.0934 -0.6637 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 6.6261 4.7788 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -3.2215 -1.1160 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 5.9538 6.8479 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -4.4903 -0.9544 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 5.1795 7.8659 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.0000 -0.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0.0000 -1.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 4.0000 1.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 5.0000 2.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.0000 -1.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3.0000 0.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.0000 2.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.0000 3.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -0.0000 1.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 4.0000 3.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -2.6456 1.4067 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 4.0570 5.0878 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.0000 0.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3.0000 2.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.0000 1.0000 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0.0000 -0.0000 0.0000 P 0 0 3 0 0 0 0 0 0 0 0 0 4.0000 2.0000 0.0000 P 0 0 3 0 0 0 0 0 0 0 0 0 2.0000 0.0000 0.0000 P 0 0 3 0 0 0 0 0 0 0 0 0 2.0000 2.0000 0.0000 P 0 0 3 0 0 0 0 0 0 0 0 0 1 3 2 0 0 0 0 1 9 1 0 0 0 0 2 4 2 0 0 0 0 2 10 1 0 0 0 0 3 21 1 0 0 0 0 4 22 1 0 0 0 0 5 39 1 0 0 0 0 6 40 1 0 0 0 0 7 5 1 6 0 0 0 7 11 1 0 0 0 0 7 41 1 0 0 0 0 8 6 1 1 0 0 0 8 12 1 0 0 0 0 8 42 1 0 0 0 0 9 19 2 0 0 0 0 9 23 1 0 0 0 0 10 20 2 0 0 0 0 10 24 1 0 0 0 0 11 13 1 0 0 0 0 11 25 1 1 0 0 0 12 14 1 0 0 0 0 12 26 1 6 0 0 0 13 15 1 0 0 0 0 13 27 1 1 0 0 0 14 16 1 0 0 0 0 14 28 1 6 0 0 0 15 21 1 6 0 0 0 15 41 1 0 0 0 0 16 22 1 1 0 0 0 16 42 1 0 0 0 0 17 19 1 0 0 0 0 17 21 1 0 0 0 0 17 29 2 0 0 0 0 18 20 1 0 0 0 0 18 22 1 0 0 0 0 18 30 2 0 0 0 0 31 46 1 0 0 0 0 32 46 2 0 0 0 0 33 47 1 0 0 0 0 34 47 2 0 0 0 0 35 48 1 0 0 0 0 36 48 2 0 0 0 0 37 49 1 0 0 0 0 38 49 2 0 0 0 0 39 46 1 0 0 0 0 40 47 1 0 0 0 0 43 46 1 0 0 0 0 43 48 1 0 0 0 0 44 47 1 0 0 0 0 44 49 1 0 0 0 0 45 48 1 0 0 0 0 45 49 1 0 0 0 0 M END $$$$

Physi-Chem Properties

Molecular Weight:	789.99
Volume:	595.311
LogP:	-4.081
LogD:	-2.46
LogS:	0.366
# Rotatable Bonds:	14
TPSA:	391.81
# H-Bond Aceptor:	27
# H-Bond Donor:	6
# Rings:	4
# Heavy Atoms:	31

MedChem Properties

QED Drug-Likeness Score:	0.101
Synthetic Accessibility Score:	6.408
Fsp3:	0.556
Lipinski Rule-of-5:	Rejected
Pfizer Rule:	Accepted
GSK Rule:	Rejected
BMS Rule:	0
Golden Triangle Rule:	Rejected
Chelating Alert:	0
PAINS Alert:	0

ADMET Properties (ADMETlab2.0)

ADMET: Absorption

Caco-2 Permeability:	-7.222
MDCK Permeability:	5.995973333483562e-05
Pgp-inhibitor:	0.0
Pgp-substrate:	0.062
Human Intestinal Absorption (HIA):	1.0
20% Bioavailability (F20%):	1.0
30% Bioavailability (F30%):	1.0

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB):	0.454
Plasma Protein Binding (PPB):	8.680929183959961%
Volume Distribution (VD):	0.374
Pgp-substrate:	55.06203079223633%

ADMET: Metabolism

CYP1A2-inhibitor:	0.0
CYP1A2-substrate:	0.025
CYP2C19-inhibitor:	0.021
CYP2C19-substrate:	0.009
CYP2C9-inhibitor:	0.0
CYP2C9-substrate:	0.047
CYP2D6-inhibitor:	0.032
CYP2D6-substrate:	0.021
CYP3A4-inhibitor:	0.0
CYP3A4-substrate:	0.0

ADMET: Excretion

Clearance (CL):	1.689
Half-life (T1/2):	0.877

ADMET: Toxicity

hERG Blockers:	0.001
Human Hepatotoxicity (H-HT):	0.2
Drug-inuced Liver Injury (DILI):	0.996
AMES Toxicity:	0.053
Rat Oral Acute Toxicity:	0.0
Maximum Recommended Daily Dose:	0.925
Skin Sensitization:	0.611
Carcinogencity:	0.379
Eye Corrosion:	0.003
Eye Irritation:	0.007
Respiratory Toxicity:	0.233

Download Data

Data Type	Select
General Info & Identifiers & Properties
Structure MOL file
Source Organisms
Biological Activities
Similar NPs/Drugs

Natural Product: NPC329277

Natural Product ID:	NPC329277
*Common Name:**	Diquafosol
IUPAC Name:	[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
Synonyms:	Diquafosol; INS-365
Standard InCHIKey:	NMLMACJWHPHKGR-NCOIDOBVSA-N
Standard InCHI:	InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
SMILES:	O[C@@H]1[C@@H](COP(=O)(OP(=O)(OP(=O)(OP(=O)(OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)n2ccc(nc2=O)O)O)O)O)O)O[C@H]([C@@H]1O)n1ccc(nc1=O)O
Synthetic Gene Cluster:	n.a.
ChEMBL Identifier:	CHEMBL221326
PubChem CID:	148197
Chemical Classification:**	CHEMONTID:0000000 [Organic compounds] [CHEMONTID:0000289] Nucleosides, nucleotides, and analogues [CHEMONTID:0003468] (5'->5')-dinucleotides

*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.

Species Source

Organism ID	Organism Name	Taxonomy Level	Family	SuperKingdom	Isolation Part	Collection Location	Collection Time	Reference
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	DOI[10.1172/JCI16309]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	DOI[10.1371/journal.pone.0115359]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[10557354]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[11034610]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[11419736]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[11530998]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[1175644]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[12391014]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[12812989]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[12840027]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[12878451]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[15084647]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[1521032]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[15230696]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[15314235]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[16112079]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[16770722]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[1687010]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[17116739]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[17190852]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[17875433]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[18311922]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[18544912]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[18799520]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[19425150]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[19961175]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[20506249]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[20601097]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	faeces	n.a.	PMID[20708442]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	bile	n.a.	PMID[20708442]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	urine	n.a.	PMID[20708442]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[20876113]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[21798258]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[2268561]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[22711758]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23315938]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23717534]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23752203]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23810710]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23811455]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23868375]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[23919613]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[24101735]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[24399466]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[24494566]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[24558969]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[24816727]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[25114169]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[25181601]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[25293588]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[25644343]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[26236990]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[27471436]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[3179836]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[347637]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[4696527]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[5432584]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[6121420]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[6780563]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[8600370]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[8987136]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[9192820]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	PMID[9800648]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	Database[MetaboLights]
NPO20338	Mus musculus	Species	Muridae	Eukaryota	n.a.	n.a.	n.a.	Database[UNPD]

☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].

NP Quantity Composition/Concentration

Organism ID	NP ID	Organism Material Preparation	Organism Part	NP Quantity (Standard)	NP Quantity (Minimum)	NP Quantity (Maximum)	Quantity Unit	Reference

☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].

Biological Activity

Activity Type	# Activity
EC50	21
Others	15

Activity Type	# Activity
Individual Protein	32
ORGANISM	2
Others	1
SINGLE PROTEIN	1

Target ID	Target Type	Target Name	Target Organism	Activity Type	Activity Relation	Value	Unit	Reference
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	210.0	nM	PMID[532935]
NPT3827	Individual Protein	Pyrimidinergic receptor P2Y4	Homo sapiens	EC50	=	130.0	nM	PMID[532935]
NPT1391	Individual Protein	Pyrimidinergic receptor P2Y6	Homo sapiens	EC50	=	20000.0	nM	PMID[532935]
NPT3825	Individual Protein	Purinergic receptor P2Y1	Homo sapiens	EC50	>	20000.0	nM	PMID[532936]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	210.0	nM	PMID[532937]
NPT3827	Individual Protein	Pyrimidinergic receptor P2Y4	Homo sapiens	EC50	=	130.0	nM	PMID[532937]
NPT1391	Individual Protein	Pyrimidinergic receptor P2Y6	Homo sapiens	EC50	=	1160.0	nM	PMID[532937]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	60.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	112.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	270000.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	179.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	94.5	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	394.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	572.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	419.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	620000.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	145.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	216.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	231.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	>	300000.0	nM	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	98.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	142.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	101.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	102.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	72.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	25.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	85.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	127.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Efficacy	=	5.0	%	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	Ratio EC50	=	25.0	n.a.	PMID[532938]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	100.0	nM	PMID[532939]
NPT3826	Individual Protein	Purinergic receptor P2Y2	Homo sapiens	EC50	=	60.0	nM	PMID[532940]
NPT27	Others	Unspecified		Drug degradation	=	18.0	%	PMID[532940]
NPT20556	SINGLE PROTEIN	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	Inhibition	=	10.26	%	PMID[532941]
NPT20555	ORGANISM	SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Inhibition	=	-0.11	%	PMID[532942]

☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.

Chemically structural similarity: I. Similar Active Natural Products in NPASS

Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)

Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient

● The left chart: Distribution of similarity level between NPC329277 and all remaining natural products in the NPASS database.
● The right table: Most similar natural products (Tc>=0.56 or Top200).

range	Tanimoto Coefficient
0-0.1	560
0.1-0.2	16047
0.2-0.3	20475
0.3-0.4	4310
0.4-0.5	1066
0.5-0.6	84
0.6-0.7	89
0.7-0.8	38
0.8-0.85	14
0.85-0.9	4
0.9-0.95	9
0.95-1	1

Similarity Score	Similarity Level	Natural Product ID
0.8969	High Similarity	NPC73765
0.8969	High Similarity	NPC283698
0.8866	High Similarity	NPC36985
0.8866	High Similarity	NPC17892
0.866	High Similarity	NPC320249
0.866	High Similarity	NPC322594
0.8557	High Similarity	NPC324390
0.8491	Intermediate Similarity	NPC149843
0.8491	Intermediate Similarity	NPC155087
0.8218	Intermediate Similarity	NPC317639
0.8144	Intermediate Similarity	NPC89051
0.8144	Intermediate Similarity	NPC43246
0.7941	Intermediate Similarity	NPC318166
0.7941	Intermediate Similarity	NPC324516
0.7835	Intermediate Similarity	NPC106780
0.7745	Intermediate Similarity	NPC327344
0.757	Intermediate Similarity	NPC328914
0.7549	Intermediate Similarity	NPC315063
0.7547	Intermediate Similarity	NPC328779
0.7453	Intermediate Similarity	NPC120887
0.7438	Intermediate Similarity	NPC284651
0.7358	Intermediate Similarity	NPC280946
0.7358	Intermediate Similarity	NPC226769
0.7358	Intermediate Similarity	NPC6166
0.7353	Intermediate Similarity	NPC163352
0.7353	Intermediate Similarity	NPC210456
0.729	Intermediate Similarity	NPC90240
0.7264	Intermediate Similarity	NPC329384
0.7157	Intermediate Similarity	NPC325723
0.7059	Intermediate Similarity	NPC112842
0.7059	Intermediate Similarity	NPC71339
0.6887	Remote Similarity	NPC171116
0.6869	Remote Similarity	NPC329077
0.6698	Remote Similarity	NPC62927
0.6698	Remote Similarity	NPC190334
0.6693	Remote Similarity	NPC315058
0.6538	Remote Similarity	NPC313962
0.6471	Remote Similarity	NPC325902
0.6415	Remote Similarity	NPC229249
0.6222	Remote Similarity	NPC318142
0.6036	Remote Similarity	NPC328806
0.6031	Remote Similarity	NPC325750
0.6	Remote Similarity	NPC478024
0.5926	Remote Similarity	NPC319753
0.5922	Remote Similarity	NPC315806
0.5841	Remote Similarity	NPC109188
0.5736	Remote Similarity	NPC313813
0.5686	Remote Similarity	NPC316244

Chemically structural similarity: II. Similar Clinical/Approved Drugs

Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.

● The left chart: Distribution of similarity level between NPC329277 and all drugs/candidates.
● The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).

range	Tanimoto Coefficient
0-0.1	181
0.1-0.2	1659
0.2-0.3	3508
0.3-0.4	2300
0.4-0.5	1207
0.5-0.6	148
0.6-0.7	85
0.7-0.8	50
0.8-0.85	5
0.85-0.9	2
0.9-0.95	2
0.95-1	3

Similarity Score	Similarity Level	Drug ID	Developmental Stage
1.0	High Similarity	NPD3129	Phase 3
0.9897	High Similarity	NPD3128	Phase 3
0.9151	High Similarity	NPD3139	Phase 3
0.9057	High Similarity	NPD3138	Phase 3
0.8969	High Similarity	NPD9639	Clinical (unspecified phase)
0.8144	Intermediate Similarity	NPD9580	Clinical (unspecified phase)
0.8144	Intermediate Similarity	NPD9581	Clinical (unspecified phase)
0.7677	Intermediate Similarity	NPD9557	Clinical (unspecified phase)
0.7642	Intermediate Similarity	NPD5789	Clinical (unspecified phase)
0.757	Intermediate Similarity	NPD1455	Phase 3
0.757	Intermediate Similarity	NPD1454	Phase 3
0.75	Intermediate Similarity	NPD1686	Approved
0.7476	Intermediate Similarity	NPD9565	Discontinued
0.7273	Intermediate Similarity	NPD9556	Approved
0.7241	Intermediate Similarity	NPD7914	Suspended
0.7212	Intermediate Similarity	NPD755	Phase 3
0.72	Intermediate Similarity	NPD9561	Approved
0.72	Intermediate Similarity	NPD9560	Approved
0.7184	Intermediate Similarity	NPD241	Discontinued
0.7129	Intermediate Similarity	NPD9546	Phase 2
0.71	Intermediate Similarity	NPD9558	Phase 3
0.708	Intermediate Similarity	NPD6946	Approved
0.7064	Intermediate Similarity	NPD502	Approved
0.7059	Intermediate Similarity	NPD280	Approved
0.7059	Intermediate Similarity	NPD9533	Phase 2
0.7054	Intermediate Similarity	NPD1061	Clinical (unspecified phase)
0.6923	Remote Similarity	NPD240	Phase 3
0.6923	Remote Similarity	NPD170	Approved
0.6923	Remote Similarity	NPD9562	Discovery
0.6917	Remote Similarity	NPD7761	Suspended
0.6887	Remote Similarity	NPD841	Approved
0.6818	Remote Similarity	NPD762	Discontinued
0.6796	Remote Similarity	NPD9559	Phase 1
0.6796	Remote Similarity	NPD9529	Phase 1
0.6789	Remote Similarity	NPD501	Phase 1
0.6759	Remote Similarity	NPD251	Approved
0.6759	Remote Similarity	NPD6943	Clinical (unspecified phase)
0.6731	Remote Similarity	NPD238	Clinical (unspecified phase)
0.6731	Remote Similarity	NPD239	Phase 2
0.6698	Remote Similarity	NPD9602	Phase 3
0.6698	Remote Similarity	NPD9604	Approved
0.6698	Remote Similarity	NPD9603	Phase 3
0.6667	Remote Similarity	NPD7756	Clinical (unspecified phase)
0.6637	Remote Similarity	NPD223	Clinical (unspecified phase)
0.6606	Remote Similarity	NPD9585	Discontinued
0.6542	Remote Similarity	NPD1760	Approved
0.6522	Remote Similarity	NPD7651	Approved
0.6452	Remote Similarity	NPD7992	Clinical (unspecified phase)
0.6441	Remote Similarity	NPD1385	Discontinued
0.6415	Remote Similarity	NPD9601	Approved
0.6228	Remote Similarity	NPD514	Clinical (unspecified phase)
0.6182	Remote Similarity	NPD9553	Approved
0.6182	Remote Similarity	NPD301	Discontinued
0.6182	Remote Similarity	NPD9554	Approved
0.6148	Remote Similarity	NPD284	Phase 1
0.6134	Remote Similarity	NPD4743	Phase 2
0.6132	Remote Similarity	NPD9600	Approved
0.6106	Remote Similarity	NPD279	Clinical (unspecified phase)
0.6071	Remote Similarity	NPD267	Discontinued
0.6053	Remote Similarity	NPD215	Discontinued
0.6019	Remote Similarity	NPD9572	Clinical (unspecified phase)
0.6	Remote Similarity	NPD6948	Phase 3
0.6	Remote Similarity	NPD2633	Phase 1
0.5983	Remote Similarity	NPD192	Phase 2
0.5968	Remote Similarity	NPD1804	Phase 2
0.5968	Remote Similarity	NPD1805	Phase 2
0.5935	Remote Similarity	NPD6693	Phase 3
0.5929	Remote Similarity	NPD500	Discontinued
0.5926	Remote Similarity	NPD2691	Clinical (unspecified phase)
0.5926	Remote Similarity	NPD9573	Phase 2
0.5922	Remote Similarity	NPD9653	Clinical (unspecified phase)
0.5902	Remote Similarity	NPD1428	Phase 2
0.5888	Remote Similarity	NPD9429	Discontinued
0.5841	Remote Similarity	NPD1331	Approved
0.581	Remote Similarity	NPD9407	Approved
0.5766	Remote Similarity	NPD9555	Phase 2
0.5714	Remote Similarity	NPD3121	Phase 2
0.5692	Remote Similarity	NPD6936	Clinical (unspecified phase)
0.5692	Remote Similarity	NPD6935	Phase 3
0.5657	Remote Similarity	NPD9504	Approved
0.5657	Remote Similarity	NPD9503	Approved
0.5648	Remote Similarity	NPD9427	Approved

Bioactivity similarity: Similar Natural Products in NPASS

Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.

Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.

A: chemistry similarity

B: biological targets similarity

C: networks similarity

D: cell-based bioactivity similarity

E: similarity based on clinical data